Phase 2 Oesophageal Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older, of any gender
- People who have been diagnosed with, or are strongly suspected to have, a cancer affecting the digestive system, pancreas, liver and bile ducts, oesophagus, or gynaecological organs, and where a specific surgical procedure (HIPEC/debulking) is being planned
- People who are scheduled to have surgery to remove a tumour, or a keyhole procedure to assess how far the cancer has spread
- People who are willing to stop taking folate, folic acid, or any supplements containing folate at least 48 hours before receiving the study drug (Cytalux)
- People who are willing to provide written consent to participate, or whose legal guardian or representative is willing to do so on their behalf
Who may not be able to join:
- People with a medical condition that the trial investigators believe could put their safety at risk (confirm with trial site)
- People who have previously had a severe allergic reaction (anaphylaxis) to products containing indocyanine green, a dye used in near-infrared imaging — people with a history of unexplained severe allergic reactions will need further assessment
- People who have a known allergy to any ingredient in CYTALUX™ (pafolacianine) injection
- People who have psychological, family, social, or location-related challenges that may make it difficult to follow the trial schedule or attend follow-up appointments
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: John Waters, M.D., University of Texas Southwestern Medical Center
Phone: 214-645-7700
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Proportion of subjects with one or more NIR fluorescence positive lesion not detected under normal light and/or palpation
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.